BioRestorative Therapies

BioRestorative Therapies R&D per Employee

The R&D Spending per Employee of BioRestorative Therapies (BRTX) as of Nov 5, 2026 is 1.68 M USD. In the previous year, R&D Spending per Employee was 891,451.50 USD — a change of 88.73% (higher).

R&D per Employee

1.68 MUSD

YoY

88.73%

Last updated:

R&D Spending per Employee of BioRestorative Therapies is 2025 1.68 M USD. R&D Spending per Employee of BioRestorative Therapies was 2024 891,451.50 USD. It decreases by 88.73% higher compared to the previous year.

The BioRestorative Therapies R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
252,191.67 USD
Jan 1, 2019
287,056.33 USD
Jan 1, 2020
146,138.17 USD
Jan 1, 2021
121,509.67 USD
Jan 1, 2022
585,558.67 USD
Jan 1, 2023
672,431.83 USD
Jan 1, 2024
891,451.50 USD
Jan 1, 2025
1.68 M USD
The BioRestorative Therapies R&D per Employee history
YEARR&D per EmployeeYoY
1.68 MUSD+88.73%
891,451.50USD+32.57%
672,431.83USD+14.84%
585,558.67USD+381.90%
121,509.67USD-16.85%
146,138.17USD-49.09%
287,056.33USD+13.82%
252,191.67USD-29.70%
358,738.83USD-25.36%
480,593.83USD+36.98%
350,843.17USD+47.14%
238,435.67USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioRestorative Therapies Stock analysis

What does BioRestorative Therapies do? BioRestorative Therapies Inc generates revenue through the development and commercialization of cell-based therapeutic products. The company focuses on two primary programs: the Disc/Spine Program (brtxDISC) and the Metabolic Program (ThermoStem). Its lead product, BRTX-100, is a cell therapy formulated from autologous cultured mesenchymal stem cells derived from patients' bone marrow, designed for non-surgical treatment of lumbosacral disc disorders. The company also develops ThermoStem, a therapy using brown adipose-derived stem cells to create brown adipose tissue for metabolic conditions like obesity and diabetes. BioRestorative Therapies targets medical professionals and healthcare institutions seeking innovative cell therapies for chronic conditions, with its products in development stages focused on specific therapeutic applications. The company’s revenue model relies on the future commercialization of BRTX-100 and ThermoStem, with no current sales reported. Its proprietary production process for BRTX-100 involves collecting bone marrow, isolating and culturing stem cells, and cryopreserving them. ThermoStem’s development targets metabolic disorders, leveraging the company’s expertise in cell and tissue protocols. BioRestorative Therapies Inc operates as a life sciences firm specializing in adult stem cell therapies, with its products positioned for potential market entry in the biotechnology sector. BioRestorative Therapies Inc’s business strategy centers on advancing its pipeline of cell-based therapies, including BRTX-100 for disc disorders and ThermoStem for metabolic conditions. The company’s focus on proprietary technology and cell culture methods differentiates its approach within the biotechnology industry. While currently in development, its products aim to address unmet medical needs, targeting healthcare providers and patients with chronic conditions requiring non-surgical interventions. BioRestorative Therapies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioRestorative Therapies stock

R&D Spending per Employee of BioRestorative Therapies is 1.68 M USD in 2025.

R&D Spending per Employee of BioRestorative Therapies changed from 891,451.50 USD to 1.68 M USD, representing a 88.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee BioRestorative Therapies since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's BioRestorative Therapies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — BioRestorative Therapies

All Key Metrics — BioRestorative Therapies